Nooglutyl
Nooglutil · N-(5-hydroxynicotinoyl)-L-glutamic acid · 5-hydroxynicotinoyl-L-glutamate
Last updated
At a glance
Overview
Nooglutyl sits in a quiet corner of the nootropic catalog — a Russian-developed glutamatergic modulator that never crossed over to Western markets, but earned a steady reputation among physique-focused users looking for cognitive support that doesn't touch hormones, lipids, or sleep architecture. Structurally it's L-glutamic acid coupled to a hydroxynicotinoyl carrier — conceptually a glutamatergic mirror of picamilon — and functionally a mild AMPA-receptor positive modulator with a secondary anti-anhedonic and neuroprotective signature.
The community gravitates toward it for three overlapping use cases: as a baseline focus and verbal-fluency tool during contest prep or aggressive cuts, as a memory-stack partner alongside a choline source and occasionally noopept, and as a bridge through phenibut or benzodiazepine tapers where its dopaminergic and AMPA-side effects soften the rebound. Cruise-phase users running TRT appreciate that it has no documented interaction with HPTA, aromatase, 5α-reductase, or hepatic CYPs of interest — it adds nothing to the load a blast is already putting on the liver and lipid panel.
"The effects are very steady and cumulative, and the cognitive 'lift' was noticed after about 10 days. 100 mg once daily seemed to be the sweet spot for most users." — r/Nootropics community report (2021)
The sections below cover documented nooglutyl dosage ranges, the AMPA-modulator mechanism and what it predicts about stacking, the choline pairing that resolves the most common side-effect complaint, the GABA-withdrawal use case, and the practical pitfalls — late-day dosing, ampakine stacking, and quitting before the two-week mark — that show up repeatedly in community reports.
How Nooglutyl works
AMPA Receptor Positive Modulation#
Nooglutyl is structurally an L-glutamic acid molecule coupled to 5-hydroxynicotinic acid via an amide bond — conceptually the glutamatergic mirror of picamilon (which couples GABA to nicotinic acid). Once across the blood-brain barrier, the compound acts as a positive allosteric modulator of AMPA-subtype ionotropic glutamate receptors, facilitating fast excitatory transmission in cortical and hippocampal circuits without acting as an outright agonist. This "ampakine-like" profile is what drives the long-term potentiation (LTP) signal underlying its anti-amnesic effects, and it explains why subjective effects build over 7–14 days rather than appearing on day one — AMPA potentiation expresses through synaptic plasticity, not immediate receptor flooding.
"Nooglutyl is a glutamatergic modulator with pronounced nootropic, antiamnesic, and neuroprotective activity; its antiamnesic effect was superior to piracetam in scopolamine and electroconvulsive models of amnesia." — Voronina TA, Seredenin SB, Eksperimental'naia i Klinicheskaia Farmakologiia, 1998
The practical readout for the physique-focused user: working memory, verbal fluency, and task persistence improve without the appetite suppression, blood-pressure bump, or sleep disruption of a stimulant — useful during a cut already running caffeine, yohimbine, or clenbuterol.
Indirect Dopaminergic / Anti-Anhedonic Signature#
Chronic administration in rats reduces ³H-spiperone binding to striatal D2 receptors and blunts the locomotor hyperactivity that follows benzodiazepine withdrawal. The authors interpret this as indirect modulation of striatal dopamine tone downstream of AMPA-mediated cortical drive — not direct receptor binding.
"Long-term administration of nooglutil prevented the increase in rat locomotor activity after withdrawal from diazepam and normalized 3H-spiperone binding in the striatum." — Voronina TA et al., Bulletin of Experimental Biology and Medicine, 2002
This is the mechanistic basis for the community's most distinctive use case: bridging the anhedonic, anxious rebound that follows phenibut, kava, or benzodiazepine tapers. It is also why some users describe a mild "mood lift" component layered on top of the cognitive effect, distinguishing nooglutyl from the more neutral racetams.
Vestibular Nucleus Suppression#
Single-unit recordings from rat medial vestibular nucleus neurons show dose-dependent inhibition of caloric-stimulus-evoked firing — the neural substrate of motion sickness.
"Nooglutyl produced a dose-dependent inhibition of caloric-stimulus-evoked responses in medial vestibular nucleus neurons, indicating pronounced antimotion-sickness properties." — Yasnetsov VV et al., Bulletin of Experimental Biology and Medicine, 1995
Mechanistically distinct from anticholinergic (scopolamine) and antihistaminergic (dimenhydrinate) antimotion drugs, which is the reason it suppresses vestibular signalling without sedation or cholinergic load. Niche but real: travel-day protocols use 200 mg orally 60–90 minutes pre-flight.
Neuroprotection via Plasticity + Antioxidant Activity#
In rat models of hemorrhagic and ischemic stroke, nooglutyl reduces lesion volume and preserves passive-avoidance memory retrieval.
"Nooglutil administration reduced lesion volume and preserved memory function in rats with experimental focal cerebral ischemia." — Povarova OV et al., Eksperimental'naia i Klinicheskaia Farmakologiia, 2004
Two parallel mechanisms are credited: AMPA-mediated facilitation of synaptic plasticity in the penumbra (the salvageable tissue around an infarct), and antioxidant activity from the 5-hydroxynicotinoyl moiety, which is structurally a phenol and behaves as a radical scavenger. The same antioxidant arm is the leading hypothesis for why ampakine activation here is neuroprotective rather than excitotoxic — a fair concern with any glutamate-system compound, addressed mechanistically rather than dismissed.
Cholinergic Coupling#
Nooglutyl itself has no direct action on muscarinic or nicotinic acetylcholine receptors, but AMPA-driven cortical activation increases acetylcholine demand at the synapse. This is the mechanistic basis for the community's near-universal practice of co-administering a choline source — alpha-GPC 300 mg or CDP-choline 250 mg. AMPA potentiation without cholinergic substrate is the single most reported cause of dose-related headache, and it resolves cleanly when choline is added to the protocol rather than requiring a dose reduction.
Protocol
| Level | Dose | Frequency | Notes |
|---|---|---|---|
| Low | 50–100 mg | Twice daily | Documented entry-level range |
| Mid | 100–200 mg | Twice daily | Most commonly studied range |
| High | 200–300 mg | Twice daily | AM dose on waking; optional second dose before ~3 PM. Late-day administration is associated with insomnia. Dose–response is shallow — 100 mg is often as effective as 200 mg, and exceeding ~400 mg/day adds side effects without adding cognitive lift. |
Cycle length & outcomes
Documented cycle
4–12 weeks
Plateau after
12 wks
Cycle Notes#
Nooglutyl runs on a slow-build, plateau curve — closer to an SSRI or tianeptine in onset character than to a stimulant nootropic. The compound is non-suppressive, non-hepatotoxic, and does not interact with the HPTA, so cycle length is governed by tolerability and subjective benefit rather than by physiological recovery. Most users settle on 4–12 week blocks with a brief washout between.
| Goal | Cycle Length | Daily Dose | Frequency |
|---|---|---|---|
| Entry / tolerance check | 4 weeks | 50–100 mg | Once daily, AM |
| Cognitive baseline (cut, prep, cruise brain fog) | 6–8 weeks | 100 mg | Once daily, AM |
| Memory / study stack | 8–12 weeks | 200–400 mg | 100–200 mg AM + 100–200 mg early afternoon |
| GABAergic taper bridge (phenibut, kava, benzo) | Duration of taper + 2–4 weeks | 200–400 mg | 100–200 mg BID |
| Antimotion / pre-travel | Acute, single-day | 200–300 mg | 200 mg ~60–90 min pre-travel; optional 100 mg at +4 h |
Onset and Plateau#
The ampakine class is cumulative, not acute. Single-dose effects exist but are subtle; the meaningful cognitive lift emerges between days 7 and 14 of continuous administration, consistent with AMPA-modulator pharmacology generally.
"The effects are very steady and cumulative, and the cognitive 'lift' was noticed after about 10 days. 100 mg once daily seemed to be the sweet spot for most users." — r/Nootropics community report (2021)
Protocols should be evaluated at the two-week mark, not the second day. The most common "didn't work for me" report in the community is a four-day trial.
Loading and Tapering#
- No loading phase is required. The dose–response curve is shallow — 100 mg performs roughly as well as 200 mg in most subjects, and exceeding ~400 mg/day adds headache and irritability without adding cognitive endpoint.
- No formal taper is required. Unlike GABAergic anxiolytics or dopaminergic stimulants, nooglutyl shows no published receptor-downregulation signature. Russian chronic-dosing work actually demonstrates the opposite — normalization of striatal D2 binding after sustained administration, with no rebound on cessation (Voronina et al., 2002).
"Long-term administration of nooglutil prevented the increase in rat locomotor activity after withdrawal from diazepam and normalized 3H-spiperone binding in the striatum." — Voronina TA et al., Bulletin of Experimental Biology and Medicine (2002)
A conservative 3–5 day step-down (halve the dose, then discontinue) is reasonable when ending a longer block, but is not pharmacologically mandatory.
Dose Timing#
- AM dose on waking. AMPA facilitation is wakefulness-promoting.
- Second dose, when used, before ~3 PM. Late-day administration is the single most common cause of insomnia complaints in the community record.
- Co-administer a choline source. Alpha-GPC 300 mg or CDP-choline 250 mg alongside each dose. AMPA potentiation without cholinergic substrate is the most frequent cause of dose-related headache and the most common reason users abandon the compound prematurely.
- Oral, with or without food. Empty-stomach administration occasionally produces mild GI discomfort (the molecule is a dicarboxylic acid); a light meal resolves it.
Cycle Length and Re-Dosing#
Russian preclinical work has run nooglutyl for multi-week chronic dosing without identifying a tolerance ceiling or a withdrawal syndrome. The community pattern of 4–12 weeks on, 1–2 weeks off is conservative rather than necessary — efficacy does not measurably decay within a 12-week block, and repeat cycles can be initiated without a defined washout.
Bloodwork Cadence#
Nooglutyl is not expected to perturb lipids, liver enzymes, CBC, or hormones, and no specific monitoring is indicated by the pharmacology. Users running it alongside AAS, GH, or oral kickstarts continue their standard quarterly or mid-cycle panel — nooglutyl is a neutral neighbour on every axis those panels measure, which is precisely why it sits well inside a stacked physique protocol.
Stacking Inside a Cycle#
- With AAS / TRT cruise: Run continuously at 100 mg AM. No interaction with androgen receptor, aromatase, 5α-reductase, or hepatic CYPs of interest.
- With contest-prep stimulants (clen, yohimbine, high caffeine): Cap at 100 mg AM, single dose. The AMPA-plus-stimulant combination can produce anxiety in sensitive users — keep one or the other dialed back.
- With other ampakines (sunifiram, IDRA-21, unifiram): Do not stack. Overlapping AMPA mechanisms compound headache and irritability without a documented synergy.
- With noopept: Common community pairing — 10–20 mg noopept AM alongside nooglutyl. The two have distinct mechanistic profiles and are described as complementary rather than redundant.
Risks & mistakes
Common (most users)#
- Transient headache — the most frequently reported effect, especially in the first week or at doses above 150 mg. AMPA potentiation without adequate cholinergic substrate is the usual culprit. Mitigation: co-administer alpha-GPC 300 mg or CDP-choline 250 mg with each dose. Most "I didn't like nooglutyl" reports on r/Nootropics resolve once choline is added.
- Early-week irritability or "edge" — a mild, stimulant-adjacent restlessness in days 3–7 that typically fades as the glutamatergic facilitation settles. Mitigation: hold the dose flat rather than escalating; the dose–response is shallow and pushing higher rarely helps. Drop AM caffeine by 50% during the first week if the edge is uncomfortable.
- Insomnia from late dosing — the wakefulness-promoting profile is mild but real. Mitigation: AM dose on waking, second dose no later than ~3 PM. Single AM dosing avoids this entirely.
- Mild GI discomfort on empty stomach — the molecule carries two free carboxylic acids and is acidic in solution. Mitigation: administer with a small amount of food or a glass of water; capsule rather than loose-powder dosing helps.
- Slow subjective onset — not a side effect per se but the most common reason users abandon the protocol prematurely. The cognitive lift is cumulative over 7–14 days, consistent with the ampakine class generally.
"The effects are very steady and cumulative, and the cognitive 'lift' was noticed after about 10 days. 100 mg once daily seemed to be the sweet spot for most users." — r/Nootropics overview thread (2021)
Uncommon (dose-dependent or individual)#
- Persistent headache above 400 mg/day — exceeding ~400 mg total daily dose reliably adds side effects without adding cognitive lift. Mitigation: drop back to 200 mg/day; verify choline intake before assuming the compound is the problem.
- Anxiety or jittery affect in stimulant-sensitive subjects — AMPA facilitation stacked on top of high caffeine, clenbuterol, or yohimbine during contest prep can produce a wired, unpleasant baseline. Mitigation: separate the stimulant load from the nooglutyl dose, or drop nooglutyl during the final weeks of an aggressive cut.
- Flat or anhedonic affect at high chronic doses — a minority of long-running users (>12 weeks at 300+ mg/day) report blunting rather than enhancement, consistent with the striatal D2-binding adaptation seen in chronic-dosing rat work (Voronina et al., 2002). Mitigation: cycle 4–12 weeks on with planned breaks; do not run indefinitely at the high end.
- Diminished returns past week 12 — the efficacy curve flattens. Mitigation: scheduled 2–4 week washouts restore subjective response.
Rare but serious#
- Lowered seizure threshold — theoretical for the ampakine class generally. The published rat data (Voronina & Seredenin, 1998; Povarova et al., 2004) do not show pro-convulsant activity at therapeutic doses, but any aura, myoclonic jerk, or unexplained loss of consciousness is grounds to discontinue immediately.
- Severe anxiety or panic reaction — rare and almost always tied to stacking with other AMPA-positive modulators (sunifiram, IDRA-21, unifiram). Discontinue and remove the stacked ampakine; symptoms resolve within 24–72 hours.
Hard contraindications#
- Seizure disorder, personal or first-degree family history — AMPA potentiation in epileptogenic neural tissue is not a risk worth taking.
- Concurrent use of other AMPA-positive modulators — sunifiram, unifiram, IDRA-21, CX-516 and analogs. The dose–response of stacked ampakines is uncharacterized; headache, anxiety, and seizure risk all compound non-linearly.
- Active benzodiazepine or phenibut withdrawal without medical supervision — nooglutyl has documented benefit as a bridge (Voronina et al., 2002), but it is not a substitute for a structured taper and will not prevent withdrawal seizures.
- Pregnancy and lactation — safety has not been characterized; default exclusion.
Gender considerations and PCT#
Nooglutyl has no documented effect on the HPTA, androgen receptor, aromatase, 5α-reductase, prolactin, or the hepatic CYPs relevant to AAS users. No PCT implications — the compound does not require ancillaries, suppress endogenous hormones, or interact mechanistically with SERMs or aromatase inhibitors. Female subjects have no specific contraindication on the published record beyond the pregnancy/lactation exclusion above; standard dosing applies across the subject pool. This places nooglutyl in the same "neutral neighbour" category as ALCAR or low-dose tianeptine — a cognitive support compound that can sit on top of a blast, cruise, or PCT without adding load to a panel that is already managing AAS, orals, or peptides.
FAQ — Nooglutyl
Research & citations
6 studies cited on this page.
Conclusion
Nooglutyl stands out as a research nootropic with a mild, cumulative AMPAkine signature — supporting memory, verbal fluency, and resilience in demanding protocols without stimulant risks or HPTA interaction.
Key takeaways:
- Typical oral dose: 100–200 mg once or twice daily, with the last dose before 3 PM to avoid insomnia
- Cycle length: 4–12 weeks; most protocols run 6–8 weeks for full cumulative effect
- Choline source (300 mg alpha-GPC or 250 mg CDP-choline) is frequently stacked to eliminate headache and maximize cognitive lift
- Headline benefit: reliable working-memory and mood support through AMPA facilitation, with standout safety for AAS or calorie-restricted protocols
- Key use cases: contest prep brain fog, cruise-phase maintenance, phenibut/benzo-taper bridge, and antimotion support
- Dose–response curve is shallow — pushing past 300–400 mg/day does not add measurable benefit and raises headache/irritability risk
In any cognition-focused research stack requiring AMPA or dopaminergic lift with minimal downside, nooglutyl covers the brief: simple, stack-friendly, and supported by both old-school literature and current peer community logs.